[en] BACKGROUND AND OBJECTIVE: To compare intubation conditions and time-course of action of rocuronium and mivacurium for day case anaesthesia. METHODS: Fifty ASA I or II patients were enrolled. Anaesthesia was induced with propofol using a target controlled infusion system (target 6-8 microg mL(-1) ) and sufentanil (0.25 microg mL(-1). It was maintained with propofol (target 3.5-4.5 microg mL(-1) and 50% nitrous oxide in oxygen. Muscle relaxation was achieved with either mivacurium (0.15 mg kg(-1)) or rocuronium (0.3 mg kg(-1)). Neuromuscular transmission was monitored and recorded continuously by acceleromyography using a TOF-WATCH SX (Biometer; Denmark) with supramaximal train-of-four stimulation of the ulnar nerve. Tracheal intubation was carried out by an experienced anaesthetist blinded to the type of the muscle relaxant. Intubation conditions were evaluated according to a standard scheme (ease of laryngoscopy, position of vocal cords, airway reaction and limb movements). RESULTS: Intubation conditions were good or excellent for both mivacurium 0.15 mg kg(-1) (good = 8%; excellent = 92%) and rocuronium 0.3 mg kg(-1) (excellent = 100%). Times to maximum blockade and clinical duration were not different. CONCLUSIONS: There is no significant difference between mivacurium and rocuronium concerning the onset and the recovery of muscle relaxation. Rocuronium is an alternative to mivacurium for short procedures, without the risk of unexpected prolonged relaxation due to a possible defect in plasma cholinesterase.
Savarese JJ, Kitz RJ. The quest for a short-acting non-depolarising neuromuscular blocking agent. Acta Anaesthesiol Scand 1973; 53: 43-58.
Pollard BJ, Chetty MS, Wilson A, Healy TEJ. Intubating conditions and time-course of action of low-dose rocuronium bromide in day-case dental surgery. Europ J Anaesthesiol 1995; 12(11): 81-83.
Scheller MS, Zornow MH, Saidman LJ. Tracheal intubation without the use of muscle relaxants: a technique using propofol and varying doses of alfentanil. Anesth Analg 1992; 75: 788-793.
Savarese JJ, Ali HH, Basta SJ et al. The clinical neuromuscular pharmacology of mivacurium bromide (BW1090U). Anesthesiology 1988; 68: 723-732.
Pino RM, Ali HH, Denman WT, Barrett PS, Schwarz A. A comparison of the intubation conditions between mivacurium and rocuronium during balanced anesthesia. Anesthesiology 1998; 88: 673-678.
Prien Th, Zahn P, Menges M, Brüssel Th. 1xD90 dose of rocuronium bromide: tracheal intubation conditions and time-course of action. Eur J Anaesthesiol 1995; 12: 85-90.
Pühringer FK, Khuenl-Brady KS, Koller J, Mitterschiffhaler G. Evaluation of the endotracheal intubating conditions of rocuronium and succinylcholine in outpatient surgery. Anesth Analg 1992; 75: 37-40.
Tang J, Joshi GP, White PF. Comparison of rocuronium and mivacurium to succinylcholine during outpatient laparoscopic surgery. Anesth Analg 1996; 82: 994-998.
Mellinghoff H, Diefenbach C, Bischoff A, Grond S, Buzello W. Dose-response relationship of rocuronium bromide during intravenous anaesthesia. Eur J Anaesthesiol 1994; 11(Suppl 9): 20-24.
Meistelman C, Plaude B, Donati F. Rocuronium neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans. Can J Anesthesia 1992; 39: 665-669.
Wierda JMKH. Rocuronium for muscle relaxation in ambulatory patients. In: Crul JF, ed. Clinical Aspects of Rocuronium Bromide. Turnhout, Belgium: Interface, 1996: 19-27.
Barclay K, Eggers K, Asai T. Low-dose rocuronium improves conditions for tracheal intubation after induction or anaesthesia with propofol and alfentanil. Br J Anaesth 1997; 78(1): 92-94.
Robertson EN, Driessen JJ, Vogt M, De Boer H, Scheffer J. Pharmacodynamics of rocuronium 0.3 mg kg-1 in adult patients with and without renal failure. Eur J Anaesthesiol 2005; 22: 929-932.
Booij LHD, Knape HTA. The neuromuscular blocking effect of Org 9426. A new intermediately-acting steroidal non depolarising muscle relaxant in man. Anaesthesia 1991; 46: 341-343.
Levy JH, Davis GK, Duggan J, Szlam F. Determination of hemodynamics and histamine release of rocuronium when administered in increased doses under N2O/O2-sufentanil anesthesia. Anesth Analg 1994; 78: 318-321.
Ostergaard D, Jensen E, Jensen FS et al. The duration of action of mivacurium induced block in patients homozygous for the atypical plasma cholinesterase gene. Anesthesiology 1991; 75: A774.
Goudsouzian NG, D'Hollander AA, Viby-Mogensen J. Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency. Anesth Analg 1993; 77(1): 183-185.
Cook DR, Freeman JA, Lai AA et al. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992; 69(6): 580-585.
Khuenl-Brady KS, Pomaroli A, Pühringer F et al. The use of rocuronium in patients with chronic renal failure. Anaesthesia 1993; 48: 873-875.
Cooper RA, Maddineni VR, Mirakhur RK et al. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 71: 222-226.
Robertson EN, Driesen JJ, Vogt M, De Boer H, Scheffer GJ. Pharmacodynamics of rocuronium 0.3 mg kg-1 in adult patients with and without renal failure. Eur J Anaesthesiol 2005; 22: 929-932.
Khalil M, D'Honneur G, Duvaldestin P et al. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994; 80: 1241-1247.
Magorian T, Wood P, Caldwell J et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80: 754-759.
Mertes PM, Laxenaire MC, Alla F. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003; 99: 536-545.
Laxenaire MC, Mertes PM. Anaphylaxis during anaesthesia: results of a two-year survey in France. Br J Anaesth 2001; 87: 549-558.
Guttormsen AB. Allergic reactions during anaesthesia: increased attention to the problem in Denmark and Norway. Acta Anaesthesiol Scand 2001; 45: 1189-1190.
Bhananker SM, O'Donnell JT, Salemi JR, Bishop MJ. The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: an analysis of Food and Drug Administration reporting of adverse events. Anesth Analg 2005; 101: 819-822.
